Gene associated with leishmania parasite virulence
US7700121B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 12, 2003 |
| Grant date | Apr 20, 2010 |
| Priority date | — |
| Expiry date | Dec 25, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerases (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.